ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo (PBO) plus carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: 0285a1bbb25561e97758c07ee35190e587e5c54d
First added on: Dec 20, 2022